Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease.
Ragland, D.A., Nalivaika, E.A., Nalam, M.N., Prachanronarong, K.L., Cao, H., Bandaranayake, R.M., Cai, Y., Kurt-Yilmaz, N., Schiffer, C.A.(2014) J Am Chem Soc 136: 11956-11963
- PubMed: 25091085 
- DOI: 10.1021/ja504096m
- Primary Citation of Related Structures:  
4Q1W, 4Q1X, 4Q1Y - PubMed Abstract: 
HIV-1 protease inhibitors are part of the highly active antiretroviral therapy effectively used in the treatment of HIV infection and AIDS. Darunavir (DRV) is the most potent of these inhibitors, soliciting drug resistance only when a complex combination of mutations occur both inside and outside the protease active site ...